# RUO Peptide Regulation Explained: What FDA, FTC and DEA Have Published > A plain guide to the official FDA, FTC and DEA documents that research-use-only peptide sellers should read. Dated sources only. Not legal advice. Updated: 2026-10-31 ยท https://researchpay.io/blog/ruo-peptide-regulation-explained Compliance-adjacent. Not legal advice. This page points to what federal agencies have published. It does not say what any business may or may not sell. Talk to a lawyer about your own products. The short version: FDA looks at how a product is presented, not only at its label. In a March 31, 2026 [warning letter](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gram-peptides-721806-03312026), FDA said a seller's "Research Use Only" statements did not change its finding, because the website showed the products were intended for human use. ## Where does the phrase "research use only" come from? From FDA's rules for in vitro diagnostic products. [21 CFR 809.10(c)(2)(i)](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-809/subpart-B/section-809.10) uses the statement "For Research Use Only. Not for use in diagnostic procedures." for products in the laboratory research phase. The section was last amended at 81 FR 38391 (June 15, 2016). FDA explains its thinking on that label in [Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/distribution-vitro-diagnostic-products-labeled-research-use-only-or-investigational-use-only), guidance dated November 2013 (docket FDA-2011-D-0305). ## How does FDA decide what a product is intended for? FDA's intended use rule is [21 CFR 201.128](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-201/subpart-G/section-201.128), last amended in the Federal Register at 86 FR 41401 (August 2, 2021). FDA's warning letters cite it when they point to website and labeling claims as evidence of intended use. ## What did FDA say in its 2026 peptide warning letter? In its [March 31, 2026 letter to Gram Peptides](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gram-peptides-721806-03312026), FDA said: - Despite "Research Use Only" and "not intended for human consumption" statements, evidence from the website showed the products were intended as drugs for human use. - Product page claims about appetite, body weight and glucose were cited as evidence of intended use under 21 CFR 201.128. - Bacteriostatic water sold alongside the peptides was treated as a drug, because selling them together showed intent to inject. - The products were found to be unapproved new drugs under section 505(a) of the FD&C Act. ## What does the FTC say about health claims? The FTC issued its [Health Products Compliance Guidance](https://search.ftc.gov/business-guidance/resources/health-products-compliance-guidance) on [December 20, 2022](https://search.ftc.gov/news-events/news/press-releases/2022/12/ftc-announces-new-business-guidance-marketers-sellers-health-products). It says advertising must be truthful and not misleading, and that health claims generally need competent and reliable scientific evidence. The FTC says the guide is not a safe harbor. ## Where does the DEA fit? DEA publishes the [controlled substances list](https://www.deadiversion.usdoj.gov/schedules/orangebook/c_cs_alpha.pdf) by schedule (read Oct 31, 2026). It includes anabolic steroids in Schedule III and many synthetic compounds in Schedule I. Check every catalog item against the current list. ## Why do payment banks care? A bank takes on the merchant's legal and dispute risk. Underwriters read the same agency documents and then read the store's website. See our [compliance guide](/blog/peptide-payment-processing-compliance-guide) and [RUO website checklist](/blog/ruo-website-compliance-checklist) for what they look for. - [Chargebacks for RUO merchants](/blog/chargebacks-for-ruo-merchants) ## Sources - [21 CFR 809.10, Labeling for in vitro diagnostic products](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-809/subpart-B/section-809.10), eCFR / Federal Register, last amended 81 FR 38391, June 15, 2016 - [Distribution of IVD Products Labeled for Research Use Only or Investigational Use Only](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/distribution-vitro-diagnostic-products-labeled-research-use-only-or-investigational-use-only), FDA, November 2013 - [21 CFR 201.128, Meaning of intended uses](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-201/subpart-G/section-201.128), eCFR / Federal Register, last amended 86 FR 41401, Aug 2, 2021 - [Warning letter, Gram Peptides, MARCS-CMS 721806](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gram-peptides-721806-03312026), FDA, Mar 31, 2026 - [Health Products Compliance Guidance](https://search.ftc.gov/business-guidance/resources/health-products-compliance-guidance), FTC, Dec 20, 2022 - [Controlled Substances, Alphabetical Order](https://www.deadiversion.usdoj.gov/schedules/orangebook/c_cs_alpha.pdf), DEA Diversion Control Division, read Oct 31, 2026 Compliance-adjacent content. This is general information, not legal advice, and it does not say what any product or business is allowed to do. ResearchPay works only with merchants that sell products labeled and marketed for research use only, not for human or animal use.